ClinicalTrials.gg
RecruitingNCT07309562Updated May 8, 2026

The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age

A Phase 3 interventional study of Inpegsomatropin Injection and Inpegsomatropin Injection in Small for Gestational Age, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Recruiting at 49 sites in China. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Study summary

This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection,once a week,compared with recombinant human growth hormone (rhGH) in children with short stature born small for gestational age (SGA).It plans to enroll 141 children with short stature born small for gestational age (SGA), who will be stratified by gender and age and randomized in a 1:1:1 ratio to either Experimental Group 1, Experimental Group 2, or the Active Control Group. All participants will undergo a screening period (up to 12 weeks), a treatment period (52 weeks), and a post-treatment follow-up period (5 weeks). Safety and efficacy will be comprehensively evaluated.

02

Conditions studied

  • Small for Gestational Age

Keywords

  • Inpegsomatropin Injection
  • Recombinant Human Growth Hormone Injection
03

In context

Lead sponsor

Xiamen Amoytop Biotech Co., Ltd. is the lead sponsor of 32 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prepubertal (Tanner stage I) children: boys aged ≥2 and \<11 years, and girls aged ≥2 and \<10 years at screening.
  • Bone age is not more than 1 year advanced or more than 2 years delayed compared to chronological age (i.e., -2 years ≤ bone age - chronological age ≤ 1 year).
  • Birth weight and/or length below the 10th percentile for gestational age and sex, according to the reference values in Appendix 1.
  • Gestational age at birth ≥28 weeks.
  • Height at screening below -2 SD for age and sex, according to the reference values in Appendix 2.
  • (BMI) between the 5th and 95th percentiles for age and sex, according to the reference values in Appendix 3.
  • Peak GH level ≥10.0 ng/mL in at least one prior GH stimulation test.
  • No prior systemic growth-promoting therapy (used continuously for ≥1 month), including but not limited to growth hormone, insulin-like growth factor-1 (IGF-1), etc.
  • Legal guardian has provided written . If the participant is ≥8 years old, they must also provide written assent. For participants under 8 years old who are capable of expressing agreement, their assent should be formally documented.

Exclusion criteria

Exclusion Criteria:

  • Subjects with closed epiphyses.
  • Subjects with other types of growth abnormalities, including confirmed or highly suspected growth hormone deficiency (GHD), Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, Turner syndrome, short stature due to GH receptor deficiency, short stature due to growth plate-related gene abnormalities (e.g., SHOX gene anomalies), growth retardation due to malnutrition, or growth retardation due to hypothyroidism.
  • Participation in any other clinical trial with drug or non-drug interventions within 3 months prior to screening.
  • Use of inhaled for more than 2 consecutive weeks, or oral/intravenous corticosteroids for more than 1 consecutive week, within 3 months prior to screening.
  • Current or long-term requirement for therapies that may affect growth, including but not limited to methylphenidate, sex hormones, gonadotropin-releasing hormone analogs, aromatase inhibitors, anabolic agents, or insulin.
  • Abnormal liver or kidney function at screening ( > 1.5 times the [ULN], Cr > ULN).
  • Diagnosis of diabetes mellitus, or two consecutive fasting blood glucose measurements ≥ 6.1 mmol/L prior to randomization.
  • Chronic infectious diseases which, in the investigator's judgment, may affect study participation (e.g., chronic ).
  • Systemic chronic diseases, such as chronic kidney disease, severe cardiovascular diseases, or psychiatric/psychological disorders.
  • Congenital skeletal dysplasia, scoliosis exceeding 15°, limping gait, or a prior diagnosis of slipped capital femoral epiphysis.
  • History of intracranial hypertension.
  • Past or current history of malignant tumors, including intracranial tumors.
  • Known allergy to growth hormone or any of its .
  • Any other condition deemed by the investigator as inappropriate for participation in this clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (estimated)

Study arms

  • Experimental
    Experimental Group 1

    Drug: Inpegsomatropin Injection

  • Experimental
    Experimental Group 2

    Drug: Inpegsomatropin Injection

  • Active comparator
    rhGH group

    Drug: Recombinant Human Growth Hormone Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Growth velocity (HV, cm/year).

    Time frame: Week 52

Secondary outcomes

  1. Change in height standard deviation score from baseline (△HT SDS)

    Time frame: From baseline to all follow-up time points at Week 52

  2. Change in growth velocity from baseline (△HV)

    Time frame: From baseline to all follow-up time points at Week 52

  3. Change in insulin-like growth factor 1 standard deviation score from baseline (△IGF-1 SDS)

    Time frame: From baseline to all follow-up time points at Week 52

  4. Ratio of the change in bone age to the change in chronological age

    Time frame: Week 52

07

Study locations

49 of 49 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 30, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Mar 2028
CompletionEst.
May 7, 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07309562
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Jan 20, 2026
Primary completion
Mar 2028 (estimated)
Completion
May 7, 2028 (estimated)
Last update
May 8, 2026

Study contacts

Xiaoping Luo, Ph.D
Contact
xpluo@tjh.tjmu.edu.cn
15671671188
Xiaoping Luo, Ph.D
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inpegsomatropin

Start the discussion